$2.26 Billion is the total value of PFM Health Sciences, LP's 78 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| HUM | New | HUMANA INCput | $42,671,934 | – | 87,900 | +100.0% | 1.88% | – |
| BDX | New | BECTON DICKINSON & CO | $37,381,758 | – | 151,013 | +100.0% | 1.65% | – |
| UNH | New | UNITEDHEALTH GROUP INCput | $30,576,573 | – | 64,700 | +100.0% | 1.35% | – |
| LEGN | New | LEGEND BIOTECH CORPsponsored ads | $22,767,603 | – | 472,161 | +100.0% | 1.01% | – |
| ACHC | New | ACADIA HEALTHCARE COMPANY IN | $22,465,054 | – | 310,935 | +100.0% | 0.99% | – |
| ASND | New | ASCENDIS PHARMA A/Ssponsored adr | $21,670,770 | – | 202,115 | +100.0% | 0.96% | – |
| ICUI | New | ICU MED INC | $20,241,087 | – | 122,703 | +100.0% | 0.89% | – |
| LLY | New | LILLY ELI & COcall | $13,633,774 | – | 39,700 | +100.0% | 0.60% | – |
| MRTX | New | MIRATI THERAPEUTICS INC | $11,858,487 | – | 318,948 | +100.0% | 0.52% | – |
| IMVT | New | IMMUNOVANT INC | $7,172,305 | – | 462,431 | +100.0% | 0.32% | – |
| OM | New | OUTSET MED INC | $5,979,669 | – | 324,982 | +100.0% | 0.26% | – |
| INBX | New | INHIBRX INC | $2,291,705 | – | 121,447 | +100.0% | 0.10% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MOLINA HEALTHCARE INC | 41 | Q3 2023 | 2.2% |
| HCA HOLDINGS INC | 38 | Q3 2023 | 5.2% |
| HUMANA INC | 37 | Q3 2023 | 3.8% |
| EDWARDS LIFESCIENCES CORP | 36 | Q3 2023 | 3.3% |
| UNITEDHEALTH GROUP INC | 33 | Q3 2023 | 4.8% |
| PENUMBRA INC | 33 | Q3 2023 | 4.8% |
| AERIE PHARMACEUTICALS INC | 28 | Q2 2022 | 3.7% |
| TENET HEALTHCARE CORP | 27 | Q3 2023 | 2.3% |
| ELEVANCE HEALTH INC | 26 | Q3 2023 | 4.2% |
| ICON PLC | 26 | Q3 2023 | 2.5% |
View PFM Health Sciences, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adaptimmune Therapeutics PLC | February 14, 2023 | ? | ? |
| Arcus Biosciences, Inc. | February 14, 2023 | ? | ? |
| Axsome Therapeutics, Inc. | February 14, 2023 | ? | ? |
| Erasca, Inc. | February 14, 2023 | ? | ? |
| Generation Bio Co. | February 14, 2023 | ? | ? |
| IO Biotech, Inc. | February 14, 2023 | ? | ? |
| Jounce Therapeutics, Inc. | February 14, 2023 | ? | ? |
| Outset Medical, Inc. | February 14, 2023 | ? | ? |
| uniQure N.V. | February 14, 2023 | ? | ? |
| AERIE PHARMACEUTICALS INC | February 14, 2022 | ? | ? |
View PFM Health Sciences, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G | 2023-04-21 |
View PFM Health Sciences, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.